Keros Therapeutics, Inc.

NasdaqGM:KROS Rapporto sulle azioni

Cap. di mercato: US$2.8b

Keros Therapeutics Gestione

Gestione criteri di controllo 2/4

Keros Therapeutics Il CEO è Jas Seehra, nominato in Dec2015, e ha un mandato di 8.92 anni. la retribuzione annua totale è $ 8.93M, composta da 7.3% di stipendio e 92.7% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.62% delle azioni della società, per un valore di $ 17.17M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.4 anni e 4.7 anni.

Informazioni chiave

Jas Seehra

Amministratore delegato

US$8.9m

Compenso totale

Percentuale dello stipendio del CEO7.3%
Mandato del CEO8.9yrs
Proprietà del CEO0.6%
Durata media del management3.4yrs
Durata media del Consiglio di amministrazione4.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation

Aug 07
Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation

Keros Therapeutics: Potential Beyond KER-050 For Targeting Of Blood Cancers

Jun 10

Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 41%?

Apr 23
Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 41%?

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Sep 24
We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth

Jun 10
We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Dec 25
Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Sep 08
Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Keros Therapeutics GAAP EPS of -$1.13 misses by $0.07

Aug 04

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Apr 29
Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Jan 24
We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Oct 10
Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

May 05
We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Are Insiders Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Stock?

Mar 13
Are Insiders Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Stock?

We're Not Very Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Rate

Jan 19
We're Not Very Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Rate

Have Insiders Been Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Shares?

Nov 27
Have Insiders Been Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Shares?

Keros Therapeutics prices equity offering at $50

Nov 13

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Jas Seehra rispetto agli utili di Keros Therapeutics?
DataCompenso totaleStipendioGuadagni aziendali
Sep 30 2024n/an/a

-US$182m

Jun 30 2024n/an/a

-US$168m

Mar 31 2024n/an/a

-US$160m

Dec 31 2023US$9mUS$649k

-US$153m

Sep 30 2023n/an/a

-US$142m

Jun 30 2023n/an/a

-US$127m

Mar 31 2023n/an/a

-US$116m

Dec 31 2022US$6mUS$611k

-US$105m

Sep 30 2022n/an/a

-US$82m

Jun 30 2022n/an/a

-US$79m

Mar 31 2022n/an/a

-US$67m

Dec 31 2021US$7mUS$557k

-US$59m

Sep 30 2021n/an/a

-US$61m

Jun 30 2021n/an/a

-US$53m

Mar 31 2021n/an/a

-US$49m

Dec 31 2020US$10mUS$521k

-US$45m

Sep 30 2020n/an/a

-US$39m

Jun 30 2020n/an/a

-US$31m

Mar 31 2020n/an/a

-US$23m

Dec 31 2019US$695kUS$485k

-US$14m

Compensazione vs Mercato: La retribuzione totale di Jas ($USD 8.93M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 6.59M ).

Compensazione vs guadagni: La retribuzione di Jas è aumentata nonostante l'azienda non sia redditizia.


AMMINISTRATORE DELEGATO

Jas Seehra (68 yo)

8.9yrs

Mandato

US$8,932,076

Compensazione

Dr. Jasbir S. Seehra, also known as Jas, Ph D., has been Chief Executive Officer and Director at Keros Therapeutics Inc., since December 2015 and is its Chair of the Board since July 1, 2024 and was its Pr...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Jasbir Seehra
CEO & Chair of the Board8.9yrsUS$8.93m0.62%
$ 17.2m
Christopher Rovaldi
President & COO2.8yrsUS$4.69m0%
$ 0
Keith Regnante
Chief Financial Officer4.8yrsUS$2.20m0%
$ 0
Esther Cho
Senior VP4.6yrsNessun datoNessun dato
Robin Wagner
Senior Vice President of Human Resources3.4yrsNessun datoNessun dato
John Oram
Senior Vice President of Program & Portfolio Management1.6yrsNessun datoNessun dato
Yung Chyung
Chief Medical Officerno dataNessun datoNessun dato

3.4yrs

Durata media

52yo

Età media

Gestione esperta: Il team dirigenziale di KROS è considerato esperto (durata media dell'incarico 3.4 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Jasbir Seehra
CEO & Chair of the Board8.9yrsUS$8.93m0.62%
$ 17.2m
Carl Gordon
Independent Director4.7yrsUS$409.37kNessun dato
Tomer Kariv
Independent Director4.8yrsUS$385.86kNessun dato
Jean-Jacques Bienaime
Lead Independent Directorless than a yearNessun dato0.00049%
$ 13.5k
Julius Knowles
Independent Director8.6yrsUS$388.48k0.0029%
$ 80.9k
Mary Gray
Independent Director3.9yrsUS$396.98k0.11%
$ 2.9m
Ran Nussbaum
Independent Director8.6yrsUS$390.56k0%
$ 0
Alpna Seth
Independent Director1.5yrsUS$1.02m0.041%
$ 1.1m
Nima Farzan
Independent Director4.7yrsUS$388.48k0.087%
$ 2.4m
Mary Bouxsein
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Vicki Rosen
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Paul Yu
Member of Scientific Advisory Boardno dataNessun datoNessun dato

4.7yrs

Durata media

61yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di KROS sono considerati esperti (durata media dell'incarico 4.7 anni).